Clinical trials
Invasive Lobular Breast Carcinoma clinical trials
Below are recruiting invasive lobular breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07613151Recruiting
Lobular breast cancer with low hormone receptors
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
PadovaAges 18 years+ - NCT06184750RecruitingPhase 2
Finding the best tamoxifen dose to lower breast cancer risk
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Tucson, ArizonaAges 18–55 - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT04084730RecruitingPhase 2
3-day radiation after breast-conserving surgery for certain breast cancers
This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.
Norwalk, ConnecticutAges 45 years+ - NCT05178498Recruiting
Diet and inflammation score in women at high breast cancer risk
This study looks at whether a person’s diet that tends to cause more body inflammation is linked to future breast cancer risk. It may help researchers understand how eating patterns could affect risk in people already considered high-risk.
Columbus, OhioAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05964504Recruiting
Registry study for metastatic lobular breast cancer
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
San Diego, CaliforniaAges 18 years+ - NCT06195306RecruitingPhase 2
Low dose tamoxifen and omega-3 for breast cancer prevention
This study tests whether low-dose tamoxifen (a breast cancer prevention drug) or omega-3 supplements can lower breast cancer risk in postmenopausal women who are overweight and have a higher chance of getting the disease. The study lasts about 6 months and involves blood draws and a breast fluid test to see how the treatment affects breast cells.
Kansas City, KansasAges 45–74 - NCT06666439Recruiting
Tracking lobular breast cancer with a blood test
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT07020806RecruitingPhase 1
New imaging test for invasive lobular breast cancer that has spread
This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.
Sacramento, CaliforniaAges 18–89 - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT04985032Recruiting
Radiation after lumpectomy for selected breast tumors
This trial tests a shorter, focused type of radiation (APBI using SBRT) after lumpectomy for certain early breast cancers. It may help by targeting only the part of the breast where the tumor was, rather than treating the whole breast, while keeping safety and cancer control in mind.
Stuart, FloridaAges 50–100 - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT03909282Recruiting
Surgery now versus radiation then delayed surgery for DCIS
This trial compares two approaches for ductal carcinoma in situ (DCIS): having surgery first versus getting radiation first and then having surgery later. It aims to see which plan controls DCIS better while affecting treatment timing and outcomes.
Stanford, CaliforniaAges 18 years+ - NCT07188246RecruitingPhase 2
Radiation and immunotherapy before chemo for breast cancer
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
London, OntarioAges 18 years+ - NCT05394259RecruitingPhase 1
PYLARIFY PET-CT scan to find spread in certain cancers
This early study tests whether a special PET-CT scan called PYLARIFY can detect metastasis (cancer spread) more effectively in pancreatic, liver (HCC), and breast cancers. If the scan results change doctors’ treatment plans, it could help you get the right next therapy sooner.
Houston, TexasAges 18 years+ - NCT06958991Recruiting
Laser scanner test during breast cancer surgery
This trial tests a new laser scanner that helps doctors see if all cancer cells are removed during breast-conserving surgery, which might reduce the need for a second operation.
Villars-sûr-glâne, Canton of FribourgAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03448926Recruiting
DCIS test registry to guide radiation and drug decisions
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Scottsdale, ArizonaAges 30–85
Hear when a new Invasive Lobular Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for invasive lobular breast carcinoma?
- Yes. Clin2 currently lists 29 recruiting invasive lobular breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a invasive lobular breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a invasive lobular breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.